Drugs / γδ T cells

Trials 10 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 04 trials
Phase 0 NCT07123662 Sep 2025 → May 2028 myeloid leukemia Guangzhou Bio-gene Technology Co., Ltd Withdrawn No outcome recorded
Phase 0 NCT06364800 Apr 2024 → Apr 2026 overdue hepatocellular carcinoma Beijing 302 Hospital Not yet recruiting No outcome recorded
Phase 0 NCT04439721 May 2020 → May 2021 lymphoid leukemia PersonGen BioTherapeutics (Suzhou) Co., Ltd. Unknown No outcome recorded
Phase 0 NCT03113058 May 2017 → Oct 2018 Jinan University Guangzhou Unknown No outcome recorded
Phase 12 trials
Phase 1 NCT06196294 May 2024 → Nov 2030 expected liver cancer, lung cancer, malignant pancreatic neoplasm, mesothelioma Second Affiliated Hospital of Guangzhou Medical University Recruiting No outcome recorded
Phase 1 NCT06364787 Apr 2024 → Apr 2026 overdue hepatocellular carcinoma Beijing 302 Hospital Not yet recruiting No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT03183206 Jun 2017 → Jun 2018 breast cancer Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 1/2 NCT03180437 Jun 2017 → Jun 2018 malignant pancreatic neoplasm Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 1/2 NCT02425748 Jun → Dec 2017 lung cancer Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 1/2 NCT02425735 Apr 2015 → Jun 2016 hepatocellular carcinoma Fuda Cancer Hospital, Guangzhou Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as γδT cells “Collect blood from the patients and isolate mononuclear cells, select and grow γδT cells and transfect the γδT cells with GPC3 or Mesothelin targeting CAR” NCT06196294
9

“γδ T cells will be used against non small lung tumor.” NCT02425748

“Peripheral intravenous infusion of γδ T cells” NCT07123662

“infusion of donor γδT cellsNCT04439721

NCT02425735

NCT06364787

NCT06364800

NCT03183206

NCT03113058

NCT03180437

Modality Cell therapy “γδ T cell-based immunotherapy for CCA.” PMID 30736852 Feb 2019
Route Intravenous “via intravenous infusion of in vitro-activated allogeneic γδ Tcells” NCT03113058